CD274 and neoplasm: They developed an aptamer-functionalized targeted siRNA delivery system to facilitate immune system activation and tumor progress via programmed death ligand 1 (PD-L1) inhibition, resulting in improved anti-tumor immunity and tumor growth inhibition.